On the contrary, expression of MIR155 that promotes cardiac hypertrophy by targeting calcium signaling [59] and inhibits angiogenesis [27] showed a slight trend to increase in metformin-treated relative to non-treated groups, which aligns with the higher cardiomyocyte areas found in group M. This evidence concerns the gene MIR155 and cardiac hypertrophy.